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Glomerular immune injury in the rat: Effect of antagonists of histamine
activity. The participation of histamine via H1 and H2 receptors, in the
alteration of glomerular ultrafiltration consequent to acute glomerular
immune injury was evaluated in three groups of Munich-Wistar rats,
before and after the administration of large doses of antiglomerular
basement membrane antibody (AGBM). Group 1 was the control and
was untreated; group 2, rats continuously infused with the H receptor
antagonist diphenhydramine; and group 3, rats receiving continuous
infusion of the H2 receptor antagonist cimetidine. In group 1, nephron
filtration rate (SNGFR) decreased within 60 mm after AGBM from 58
2 to 32 5 nI . mm g kidney wt (P < 0.0005) due to decreases in
both nephron plasma flow (RPF) (291 35 to 119 23 nl min g
kidney wF') (P < 0.0005) and the glomerular permeability coefficient
(LA) (0.13 0.02 to 0.06 0.01 nI sec g kidney w1' mm Hg1)
(P < 0.01). In group 2, SNGFR decreased similarly with AGBM (59 2
to 23 10 nI' min' g kidney wt1) (P < 0.0005) due again to major
reductions in RPF and LA, suggesting no protective effect of H1
receptor blockade. In group 3, control, pre-AGBM values for SNGFR
and RPF were lower than they were in groups I and 2 due to cimetidine
infusion. SNGFR and RPF decreased but to a lesser extent in group 3
(48 3 to 41 4nI .min ' gkidney wt ')(P <0.0005). Renal vascular
resistance did not change after AGBM in this group but interpretation of
this finding is complicated because blood pressure decreased after the
antibody administration. LA decreased in group 3 as in group 1,
therefore neither H1 nor H2 receptor antagonist prevented reductions in
LA. The absence of vasoconstriction after AGBM during H2 receptor
blockade may have been a nonspecific effect of cimetidine. Histamine
plays no major role in AGBM-induced immune injury in the rat and
does not prevent a reduction in nephron filtration rate.
Lesion glomérulaire immune chez le rat: Effet des antagonistes de
I'activité de I'histamine. La participation de l'histamine, via les récep-
teurs H1 et H2, dans les modifications de l'ultraflltration glomerulaire
consecutive a une lesion glomérulaire immune aiguë a été évaluée dans
trois groupes de rats Munich-Wistar, avant et aprés l'administration de
doses élevées d'anticorps anti.membrane basale glomerulaire (AGBM);
groupe 1, contrôle et non traité; groupe 2, rats soumis a une perfusion
Continue de diphenhydramine, antagoniste du récepteur H1; groupe 3,
rats soumis a une perfusion continue de cimétidine, antagoniste du
récepteur H2. Dans le groupe 1 le debit de filtration glomérulaire des
néphrons individuels (SNGFR) diminue au cours des 60 mm consécu-
tives a l'administration d'AGBM de 58 2 a 32 5 nl min g de
poids de rein' (P < 0,0005) du fait des diminutions du debit plasma-
tique (RPF) (291 35 a 119 23 nI min' g poids de rein (P <
0,0005) et du coefficient de perméabilité glomerulaire (LA) (0,13 0,02
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a 0,06 0,01 nI sec g poids de rein' mm Hg') (P <0,01). Dans le
groupe 2, SNGFR diminue de Ia même facon aprés AGBM (59 2a 23
10 nI 'min' g poids de rein') (P < 0,0005) du fait de diminutions
importantes de RPF et LA, ce qui suggCre l'absence d'effet protecteur
du blocage des récepteurs H1. Dans le groupe 3, les valeurs contrôles,
pré AGBM, de SNGFR et RPF sont plus faibles que celles des groupes
I et 2 du fait de Ia perfusion de cimétidine, SNGFR et RPF sont
diminués dans le groupe 3 mais a un niveau inoindre (48 3 a 41 4nI'
min' g poids de rein) (P < 0,0005). La résistance vasculaire rénale
ne change pas apres AGBM dans ce groupe, mais l'interprétation de ce
résultat est rendue difficile par Ia baisse de Ia pression artérielle après
I'administration d'anticorps. LA diminue dans le groupe 3 comme
dans le groupe 1. L'absence de vasoconstriction aprCs AGBM au cours
du blocage de H2 peut avoir éte un effet non specifique de Ia cimCtidine.
L'histamine ne joue pas de role majeur dans Ia lesion immune induite
par AGBM chez le rat.
The cationic molecule, histamine, is known to be liberated
during the acute inflammatory response, and has been assumed
to play a significant role [1—31. Early studies on the inflamma-
tory events specific to glomerular immune injury have suggest-
ed strongly that use of antihistamines can diminish the severity
of experimental glomerulonephritis in animals [4—7]. These
earlier studies derived this conclusion based almost solely on
observed decreases in the magnitude of proteinuria in antihista-
mine-treated animals [4—7]. But more recent experimental stud-
ies have raised doubts as to the efficacy of blockade of
histamine action in such experimental models of renal immune
injury [8, 91. Clinical studies have also not proven a consistent
beneficial effect of histamine blockade.
We have examined the early stages of the inflammatory event
localized to the glomerulus that results from the administration
of large doses of antiglomerular basement membrane antibody
(AGBM) in the Munich-Wistar rat [10—li]. By a combination of
micropuncture, immunologic, and morphologic techniques,
glomerular immune injury was characterized by a rapid reduc-
lion in GFR within 1 hour of antibody administration [10—12].
This alteration in glomerular ultrafiltration was due to reduc-
tions in nephron plasma flow (RPF) at higher doses and
consistently related to major decreases in the glomerular per-
meability coefficient (LA). Morphologic analyses suggested
that LA reduction was related to both changes in the glomeru-
lar capillary wall and accumulation and adherence of polymor-
phonuclear leukocytes (PMN's) within the glomerular capillary
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[11, 12]. These events were highly complement dependent [Ill.
Using similar techniques in the Munich-Wistar rat, Ichikawa
and Brenner have shown that histamine infusion results in
major decreases in the glomerular permeability coefficient (K1
or LPA) and that this histamine effect was largely prevented by
concurrent infusion of H1 receptor blockers, but H2 receptor
blockers had no beneficial effect [13]. Morphologic examination
failed to reveal a basis for changes in LA (Kf) in these studies.
It is also difficult to be certain that local histamine concentra-
tions achieved during immune-induced inflammation are the
same range or greater than that produced by these investiga-
tors. Complement components (C3a and C5a) are potent stimula-
tors of histamine release from mast cells in the rat [14]. But
because of these experimental findings and the previous studies
suggesting a potential role for histamine in acute glomerular
injury, the present study was designed to examine the effects of
both H1 and H2 receptor antagonists on events during the first
hour following administration of AGBM, with micropuncture,
immunologic, and morphologic techniques [10—12].
Methods
Experiments were performed on male Munich-Wistar rats,
each weighing 200 to 260 g at the time of micropuncture. The
animals were bred and maintained on regular chow (Purina) in
an isolated colony at the Animal Research Facility at the San
Diego Veterans Administration Medical Center. Surgical prepa-
ration was as previously described [10—12], and all studies were
paired with isooncotic plasma expansion (2.5% body wt litter-
mate plasma, 1,25% body wt isotonic sodium chloride and
sodium bicarbonate administration over 1 hour) as the control
condition. A separate infusion of '4C-inulin dissolved in isoton-
ic saline and sodium bicarbonate (0.5%body wt per hour) was
begun at the time of plasma expansion and was delivered at
approximately 40 JLCi/hr.
Antiglomerular basement membrane antibody (AGBM) was
induced by immunization with GBM prepared by a modification
of the method of Krakower and Greenspon [15] and was from
the same pool used in previous studies from this laboratory [10—
12]. Nephrotoxicity of the antibody was assessed by inducing
acute proteinuria in a separate group of rats as previously
described [10, Il]. The amount of kidney-fixing antibody was
quantitated using the paired label isotope technique [16, 17].
This technique was also used to quantitate any effect of the
histamine receptor antagonists upon the binding of the anti-
body.
Experimental groups: Control group 1. After equilibration of
inulin and plasma volume expansion, initial measurements of
glomerular capillary, Bowman's space, and peritubular capil-
lary pressure measurements were made (with a servonulling
device with I- to 2-pm pipets). Samples of tubular fluid were
taken to measure single nephron glomerular filtration rate
(SNGFR), and at least three samples of efferent peritubular
capillary blood from "star" vessels were obtained [18]. Mean
arterial blood pressure (MAP), GFR, and hematocrit were
measured throughout the experimental periods.
After completion of the first measurement period, a dose of
1.4 p.g/g body wt of AGBM was administered i.v. over 5 mm in
a volume of 500 ii.! of isotonic saline and sodium bicarbonate.
Fifteen minutes after termination of AGBM infusion, all mea-
surements of pressure, filtration rates, and efferent protein
concentrations were repeated and completed within 45 miii. In
previous studies on the mechanism of glomerular immune
injury with AGBM, we have determined that inulin remains a
valid marker of glomerular filtration rate after the antibody is
administered [10].
H1 receptor blocker, group 2. Surgical preparation, inulin
equilibration, and isooncotic plasma volume expansion were
identical to the protocol for the control group. Group 2 received
a continuous i.v. infusion of 10 mg/kg body wt per hour
diphenhydramine hydrochloride (Benadryl, Parke Davis and
Co., Detroit, Michigan), an H1 receptor antagonist, initiated 30
mm prior to the start of the first measurement period. The
diphenhydramine hydrochloride was infused in a small volume
of isotonic saline and sodium bicarbonate solution throughout
the course of the experimental periods in this group. AGBM
was administered i.v. after the first period measurements were
completed as described for group I. As in the control group, all
pressure measurements, blood, tubular fluid, and urine collec-
tions were repeated within 1 hour after antibody administration.
H2 receptor blocker, group 3. Standard surgical preparation,
inulin equilibration, and isooncotic plasma expansion protocol
were used as in groups 1 and 2. Group 3 received a continuous
i.v. infusion of 345 mg/kg body wt per hour cimetidine (Smith,
Kline and French, Philadelphia, Pennsylvania) in isotonic saline
and sodium bicarbonate, begun 30 mm prior to the first mea-
surement period. The amount of cimetidine used was derived
from the doses used in infusion studies to block histamine
activity [13]. AGBM was administered i.v. over 5 mm at the
conclusion of the first period. The experimental period was
begun 15 mm after AGBM infusion and was completed within 1
hour of the AGBM administration. All pressure measurements,
blood, tubular fluid, and urine collections were duplicated in
each measurement period following the same protocol as used
in groups 1 and 2.
Analytic methods. Protein concentration in systemic and
efferent blood samples was measured by a microadaptation of
the Lowry protein method [18, 19]. GFR, SNGFR, and RBF
were determined as described in previous studies [10—12, 18].
Morphologic examination. Tissue for histologic, immunoflu-
orescent, and electron microscope examination was obtained
from both kidneys immediately following the second period of
measurements. The tissue was processed as previously de-
scribed [10—12, 20]. Light microscopic examination was used to
determine the degree of glomerular capillary encroachment that
is presumably related to endothelial abnormalities, as well as to
PMN infiltration [11, 12]. Endothelial abnormalities, foot proc-
ess fusion, and inflammatory cells, predominantly PMN's ap-
proximated to the GBM were evaluated by electron micro co-
py. The methods used were as previously described [10—12].
The paired isotope technique, as previously described [10,
11], was used to determine that the drug effects were specific
and not the result of either decreased renal delivery or fixation
of AGBM. The effects of H1 and H2 receptor antagonists on
white blood cell counts, platelet counts, hematocrit, and serum
CH50 concentrations were also evaluated as previously de-
scribed [11, 12].
Calculations and statistical analysis. Superficial nephron
filtration fraction, RPF, afferent arteriolar resistance (AR),
efferent arteriolar resistance (ER), and oncotic pressure (ir)
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from protein concentration (C) were calculated as described in
our previous publications [10—12, 18, 21].
The four factors that define the SNGFR are the hydrostatic
pressure gradient acting across the glomerular membrane (P),
the systemic oncotic pressure (ITA), the glomerular permeability
coefficient (LA), and the rate of RPF. These factors interrelate
in the following manner:
Because zP = — PBS, where PG is the directly measured
glomerular capillary hydrostatic pressure and BS is the Bow-
man's space hydrostatic pressure, the effective filtration pres-
sure (EFP) can be defined as follows:
EFP = P — IT
where ii is the oncotic pressure.
As a consequence of glomerular ultrafiltration, 'ir rises along
the length of the glomerular capillary (x*) as a result of the
increase in protein concentration (C). The mean EFP (EFP) is
defined as follows:
= f (P — ) dx
where x'1' = normalized unit glomerular capillary length.
Changes in RPF modify the EPF profile along x' by affecting
the rate at which protein is concentrated and the rate of rise in *
along xK.
The SNGFR can therefore be defined as follows:
SNGFR = LA xEFP
where LA is the glomerular permeability coefficient and which
in turn is a product of the hydraulic conductivity (Lv) of the
glomerular membrane and (A) the total filtering surface area of
the glomerular capillary.
Studies were designed as paired with experimental periods
before and after AGBM administration in each animal. The
significance of data between the pre-AGBM and post-AGBM
states in each group was determined by two-way analysis of
variance and by Student's I test where appropriate [10, 11, 22],
Also comparisons among the three groups, pre- and post-
AGBM, were made using unpaired Student's t test.
Results
Measurements were obtained both before (pre-AGBM) and
after (post-AGBM) antibody administration in the three groups
studied: group 1 control receiving only AGBM, group 2 receiv-
ing both H1 receptor antagonist diphenhydramine hydrochlo-
ride and AGBM; and group 3 receiving both H2 receptor
antagonist cimetidine and AGBM. Paired label isotope studies
performed in a separate group of rats demonstrated that the
antagonists did not alter the delivery or fixation of antibody.
The binding of small subsaturation doses of AGBM for the
control condition was 1.57 0.08 (N = 6), 1.55 0.05 (N 8)
for the diphenhydramine hydrochloride group of animals (NS),
and 1.44 0.06 (N = 6) percent binding of AGBM for the
cimetidine-infused group (NS).
Group 1: Untreated control animals. The measurements in
the control group before and after AGBM administration were
consistent with previously published results in this model.
Mean arterial pressure did not change (104 5 to 98 5 mm
Hg), consistent with previously reported values [10, III. GFR
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Fig. 1. Left Single nephron filtration rate (SNGFR) before (pre-) and
after (post-) AGBM administration, The closed circles (•) represent the
untreated control group 1; triangles (A), the H1 receptor-antagonist-
infused group 2; and the squares (•), the H2 receptor-antagonist-
infused group 3. Right The changes in renal plasma flow (RPF)for the
same groups. The asterisk (*) designates groups in which changes in
values were significant (P < 0.0005) between the pre- and post-AGBM
periods. Variance is expressed as SEM. SNGFR and RPF decreased
after AGBM administration in all groups.
values decreased significantly after antibody administration
(1.37 0.O7toO.89 0.18 ml-min 'gkidneywt, P <0.02).
The SNGFR decreased in similar proportions to the whole
kidney GFR from 58 2 to 32 5 nI ' min g kidney wt
after antibody administration (P <0.0005; Fig. 1). Both glomer-
ular capillary hydrostatic pressure (PG) and Bowman's space
pressure (PBS) decreased after the antibody (Table 1), but the
P did not change significantly (38 I to 37 1 mm Hg, NS).
Renal plasma flow and blood flow (RPF and RBF) decreased
significantly (Table 1) after antibody infusion as in previous
studies. Superficial nephron filtration fraction (SNFF) did not
change with AGBM administration (0.21 0.02 to 0.28 0.03,
NS).
The plasma protein concentration was unchanged (6.7 0.1
to 6.1 0.3 g/dl) after AGBM administration and the efferent
capillary protein concentration (CE, 8.4 0.2 to 8.5 0.3 g/dl)
also remained unchanged. Systemic oncotic pressure (IrA) was
not altered (24.0 0.6 to 21.2 1.7 mm Hg) after administra-
tion of AGBM in this untreated group. ITE, the efferent oncotic
pressure, was also unchanged (34.7 1.5 to 34.9 2.0 mm Hg)
after AGBM. The hematocrit, however, did increase after
antibody administration (42 1 to 49 I, P < 0.01).
The afferent arteriolar resistance (AR) increased from 7.4
1.3 to 19.2 3.2 x io dyne -see- cm5 (P < 0.05; Fig. 2). This
finding was similar to that of an earlier study using the same
pool of antibody [11]. The efferent arteriolar resistance also
increased from 6.7 0.9 to 15.2 2.8 X 10 dynesec-cm5 (P
< 0.02). The mean effective filtration pressure (EFP) did not
increase after the antibody administration (8.0 1.3 vs. 9.2
2.2 mm Hg). The glomerular permeability coefficient (LA)
decreased from 0.13 0.02 to 0.06 0.01 nI- sec g kidney
wt' 'mm Hg' (P <0.01) after the administration of AGBM
(Fig. 3). This finding was similar to the findings in our previous
studies using this antibody in the plasma-expanded Munich-
Wistar rat. SNGFR decreased alter AGBM, and this was the
result of major reductions in both RPF and LA.
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Table 1. Effect of histamine H1 and H2 receptor antagonists on pressures, flows, and glomerular permeabilities before and after AGBM
administrations
MAP P PBS P SNGFR RPF RBF AR ER EP LA
12 1 21212 1 2 1 212 1 2 1 2 1 2 1 2
x109 x109 n&sec"g
nlming nl'mi,r"g nlming dyne dyne kidney wU'
mm Hg mm Hg mm Hg mm Hg kidney wr' kidney wr' kidney wr' sec'cm5 seccm5 mm Hg mm Hg
Group 1 104 98 59 495 21 12" 38 37 58 32" 291 119" 505 228" 7.4 19.2" 6.7 15.2" 8 9 0.13 0.06"
control ±5 ±5 ±2 ±1 ±2±1 ±1 ±1 ±2 ±5 ±35 ±23 ±63 ±42 ±1.3 ±3.2 ±0.9 ±2.8 ±1 ±2 ±0.02 ±0.01
(N =6)
Group 2, 110 110 59 51" 21 11" 38 40 59 23" 267 81" 469 160" 8.6 3l.7" 7.0 27.Ob 10 7 0.13 0.04"
H, receptor ±5 ±4 ±3 ±2 ±2±2 ±1 ±1 ±2 ±10 ±14 ±31 ±26 ±61 ±0.3 ±6.7 ±0.7 ±7.6 ±2 ±3 ±0.03 ±0.02
antagonist
(N = 6)
Group 3, 94 80" 48 48 14 12" 34 36 48 41" 206 168" 349 284" 10.6 9.4 7.8 10.0 6 12" 0.16 0.06"
H2 receptor ±4±2 ±3 ±2 ±2±1 ±2 ±1 ±3 ±4 ±15 ±14 ±23 ±21 ±0.9 ±1.0 ±0.6 ±0.9 ±2 ±2 ±0.06 ±0.01
antagonist
(N = 6)
Values are the means ± SEM. Period 1 (pre-AGBM) is denoted b subhead 1; period 2 (post-AGBM), by subhead 2. Abbreviations are defined
in text.
Post-AGBM period (2) significantly different from pre-AGBM period (I), P < 0.05.
Group 2: Animals receiving infusion of H1 receptor antago-
nist. The continuous administration of the H1 receptor antago-
nist diphenhydramine hydrochloride did not alter any of the
measurements in the control, pre-AGBM period when com-
pared with group 1 animals. The mean arterial pressure before
antibody administration was 110 ± 5 mm Hg, and after AGBM
administration it was 110 ± 4 mm Hg. These values for MAP
were not different from those observed in both the pre- and
post-AGBM measurements in control group I (Table 1). The
GFR in group 2, control period was not different from group 1
pre-AGBM period, in spite of H1 receptor antagonist infusion
(group 1, 1.4 ± 0,1, vs. group 2, 1.7 ± 0,2 ml min g kidney
wt). The GFR decreased from 1.7 ± 0.2 to 0.7 ± 0.3 ml
min g kidney wt (P < 0.05) in group 2 after AGBM
administration. This change in GFR with AGBM was of the
same magnitude as that observed in control group 1. The
SNGFR decreased significantly as shown in Fig. 1. This magni-
tude of change in SNGFR was similar to that observed in the
control group.
Glomerular hydrostatic pressure (P0) decreased significantly
(P < 0.05) after AGBM administration (Table 1). The PBS also
decreased after antibody administration (P <0.01). Therefore,
the glomerular hydrostatic pressure gradient (P) showed no
net change after AGBM administration.
RPF decreased dramatically in the post-AGBM period. But
this post-AGBM value (81 ± 31 n1 min1 g kidney wt) is not
significantly different from the second period measurement in
the control group 1(119 ± 23 nl min' g kidney wt). RBF
also decreased significantly in the second period (Table 1).
Plasma protein concentration in systemic blood samples (Ct,;
6.4 ± 0.2 vs. 6.4 ± 0.3 gIdl) and in efferent capillary blood
samples (CE; 8.2 ± 0.3 vs. 8.7 ± 0.2 g/dl) did not change after
AGBM administration in group 2. This was similar to the
findings in the control group 1. The afferent oncotic pressure
(IrA) did not change significantly (22 ± I vs. 22 ± 2 mm Hg).
The efferent oncotic pressure also did not change significantly
after AGBM administration (lIE; 33 ± 2 vs. 36 ± 1 mm Hg). The
hematocrit did increase significantly (43 ± 1 vs. 50 ± 1, P <
0.01) as it did in the control group 1 after antibody administra-
tion.
The values for afferent arteriolar resistance (AR) increased
significantly after AGBM administration (Fig. 2) in spite of
continuous diphenhydramine hydrochloride infusion (8.6 ± 0.3
vs. 31.7 ± 6.7 x io dyne sec cm5, P < 0.05).
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Fig. 2. Changes in afferent (AR) and efferent (ER) arteriolar vascular
resistances before and after AGBM administration in the three experi-
mental groups: group 1, control and untreated (•); group 2, rats
receiving histamine H1 receptor antagonist (A); and group 3, rats
receiving histamine H2 receptor antagonist (U). Infusion of the H2
receptor antagonist (U) eliminated the normal increases in AR and ER
that occur after AGBM administration in control and H1 receptor-
antagonist-infused groups.
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Fig. 3. Glomerular permeability coefficient (L,,A), pre- and post-AGBM
administration for the untreated control group I (•), the H1 receptor-
antagonist-infused group 2 (A), and the H2 receptor-antagonist-infused
group 3 (I). Values are expressed as SEM. Infusion of H1 and H2
receptor antagonists in groups 2 and 3 did not prevent the reduction in
L1,A after AGI3M administration.
A similar finding was observed in the control group I after
AGBM. The efferent arteriolar resistance (ER) also increased
significantly after AGBM administration (7.0 0.7 vs. 27.0
7.6 x io dyne sec cm5, P < 0.05).
The mean effective filtration pressure (EFP) did not change
significantly after AGBM was administered in group 2(Table I).
The glomerular permeability coefficient (LA) decreased signif-
icantly in group 2 to the same degree as was observed after
antibody administration in group 1 (Fig. 3, Table 1). Therefore,
continuous infusion of H1 receptor antagonists did not alter the
effects of AGBM administration, and the individual determi-
nants measured were nearly identical to the untreated group 1.
Group 3: H2 receptor antagonist. The mean arterial pressure
(MAP) was lower in group 3 prior to AGBM infusion than it was
in either the control untreated group or the H1 receptor antago-
nist group (group 1, 104 5; group 2, 110 5; group 3, 94 4
mm Hg). This initial value for MAP in group 3 was also lower
than the overall mean value for MAP observed in previous
studies that used plasma expansion in this experimental model
[10, 11], suggesting an effect of cimetidine on peripheral vascu-
lar resistance after plasma expansion. Ichikawa and Brenner
found no change in arterial pressure with H2 antagonists in the
hydropenic rat [13]. The present findings may be related to
plasma volume expansion and raise the question as to whether
H2 receptor activity may be involved in vascular responses to
acute volume expansion. GFR, SNGFR, and RPF were also
numerically lower in the group 3 control state, partially as a
result of the lower MAP and possibly due to numerically higher
values for AR and ER. The GFR decreased significantly in this
groupafterAGBMinfusion(l.2 0.1 to 1.0 0.1 ml•min' g
kidney wt, P < 0.01) a decrease quantitatively less impres-
sive than that in groups 1 (control) and 2.
The SNGFR also decreased significantly after AGBM admin-
istration in the cimetidine-infused group (Table 1). But the
magnitude of the change in SNGFR was significantly less in
group 3 than in groups 1 and 2. This finding was partially the
result of the significantly lower SNGFR observed in the pre-
AGBM period (group 3, 48 3, vs. group 2, 59 2, P < 0.05;
group 3,48 3, vs. group 1,58 2, P <0.05). But there was no
statistical difference in the post-AGBM or experimental values
for SNGFR among the three separate groups, demonstrating no
overall beneficial effect of H2 histamine antagonists.
The glomerular hydrostatic pressure (PG) did not change after
AGBM administration in this group. The Bowman's space
pressure did change after AGBM (Table 1). As noted in groups
I and 2, the P also did not change between periods in the
cimetidine-infused group (Table 1). The decrease in SNGFR
was in part the result of a significant reduction in RPF in group 3
after AGBM. But, RPF decreased to a lesser extent in the H2
receptor antagonist group than it did in the control group I (P <
0.02). The control value for RPF in group 3 was significantly
lower prior to AGBM administration than that in group 1 (P <
0.05). When the post-AGBM values were analyzed as the mean
of the animal values, the difference between groups I and 3 RPF
values were not different, suggesting a similar final result. If all
individual measurements of RPF in the experimental periods
were analyzed (N 30 per group), the difference between
groups I and 3 does achieve significance (P < 0.01). The
reduction in RBF in group 3 was also slightly less during
cimetidine infusion, again primarily the result of lesser pre-
AGBM value for RBF (Table 1). Analysis of the changes in AR
and ER in group 3 reveals a major difference among groups in
response to AGBM. Only in group 3 did AR and ER not
increase after AGBM administration (Fig. 2; Table 1). This
absence of vasoconstriction with cimetidine infusion was the
major reason for the lesser reduction in RPF observed. But
interpretation of this finding is complicated by a reduction in
MAP after AGBM. It would appear that the reduction in RPF,
in contrast to groups 1 and 2, was the result of this reduction in
MAP after AGBM (94 4 to 80 2 mm Hg, P < 0.01) during
cimetidine infusion. These data then differ somewhat in group 3
H2 antagonist-infused rats in response to antibody infusion with
regard to the absence of renal vasoconstriction. Protein concen-
tration in both afferent (CA; 6.2 0.2 vs. 5.6 0.1 gldl, P <
0.01) and efferent (CE; 8.1 0.3 vs 7.4 0.1 g/dl, P < 0.05)
collections decreased in group 3. This reduction in 11Acontrib-
uted to the more modest reduction in SNGFR observed in
group 3. IrA decreased from 22 I to 19 1 mm Hg (P < 0.01),
whereas irE decreased from 33 2 to 28 1 mm Hg (P < 0.05).
The hematocrit did not change after antibody administration in
the H2 receptor antagonist-infused group (41 1 to 41 1%),
unlike the increase in hematocrit observed in the untreated
group 1. The EFP did increase after AGBM administration in
spite of the observed reduction in SNGFR in this group. EFP
did not increase in groups 1 and 2, in spite of decreases in LA,
primarily because of larger decreases in RPF. Because the
SNGFR fell but EFP increased, the LA must have decreased
significantly after AGBM as observed in groups I and 2. The
glomerular permeability coefficient, LA, decreased significant-
ly in group 3 (Fig. 3), and the magnitude of this reduction in LA
after AGBM administration was nearly identical to that ob-
served in groups 1 and 2. Therefore, cimetidine does not
prevent an immune-induced reduction in SNGFR, RPF, or
LA. But, H2 antagonists affect renal and extrarenal vascular
responses in the control and post-AGBM conditions, potential-
ly in a nonspecific manner, leading to no changes in renal
vascular resistance after AGBM.
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immunopathologic studies. Histologic studies revealed find-
ings similar to those of previous studies [10—12] and included
infiltration of polymorphonuclear (PMN) and occasional mono-
nuclear cells within the glomerular capillary lumens, which also
appeared compromised by endothelial cytoplasmic abnormali-
ties. No difference in glomerular PMN counts was noted
between the groups (group 1, 6.2 0.5, N = 6; group 2, 7.6
1.8, N =6; and group 3, 5.8 1.1, N = 6, NS). A dissociation
between the presence of PMN and AGBM effects on vascular
resistances was apparent, which had not been present in other
studies in this series. This observation is supported by the lack
of increase in AR and ER in group 3. On electron microscopic
evaluation, varying degrees of endothelial separation from the
GBM and accumulation of PMN and mononuclear cells within
the glomerular capillary lumens was noted. No overall differ-
ence in the ultrastructural findings could be enumerated be-
tween the experimental groups. By immunofluorescence micro-
scopic examination, similarly intense linear deposits of rabbit
IgG and rat C3 were present along the GBM of rats from the
three groups. In separate studies using rats prepared for micro-
puncture with plasma expansion, benadryl and cimetidine pro-
duced no decrease in white blood cell or platelet counts,
hematocrit, or serum CH50 levels. A mild leukocytosis with
increased numbers of PMN in differential counts was observed
attendant to plasma expansion.
Discussion
On the basis of the present data pertinent to the role of
histamine in acute glomerular immune injury, we must conclude
the following: (1) Histamine via its H1 receptor does not
participate in the acute alterations in glomerular function char-
acteristic of this model of AGBM-induced glomerular immune
injury. (2) Neither H1 or H2 receptors contribute to the reduc-
tion in LA observed after AGBM administration. (3) H2
receptor antagonist infusion modifies the immune-induced re-
sponses in afferent and efferent vascular resistances, but this
finding may result from rather nonspecific and extrarenal
effects of H2 receptor blockade. We have previously defined the
mechanisms whereby nephron filtration rate decreases in this
model of acute glomerular immune injury and have found that
major reductions in both RPF and LA are responsible for these
changes in glomerular ultrafiltration [10, 111. A morphologic
basis for the reduction in LA has been provided in this model,
which includes architectural changes in the glomerular capillary
wall and accumulation and attachment of inflammatory cells,
predominantly PMN's, within the glomerular capillary [10, 11].
The vasoconstriction observed has been presumed to be of
functional origin because no morphologic changes in afferent
and efferent resistance vessels have been observed [10, 11]. In
spite of the widely suggested view that histamine might alter
capillary function during inflammation [1—61, especially via
activity of its H1 receptor, the present data demonstrate that
histamine, via H1 or H2 receptors, does not participate in the
acute reduction in LA, and the H1 receptor appears to play no
role in the pathogenesis of this heterologous model of the early
stages of glomerular immune injury.
Why should we suspect that histamine, acting via either H1 or
H2 receptors, might participate in the reduction in nephron
filtration rate in the acute stage of glomerular immune injury?
Recent studies on glomerular ultrafiltration derived in the
Munich-Wistar rat provided much of the stimulus and the major
justification for the current investigation. Ichikawa and Brenner
have recently demonstrated that parenteral infusion of hista-
mine can decrease LA (Kf) and that doses of H1 receptor
blocker (diphenhydramine), identical to those used in this
study, were capable of eliminating this effect of histamine 1131.
Torres et al have also noted histamine receptors within glorner-
uli, possibly suggesting a biologic role for this compound (231.
In addition, our previous studies on AGBM-induced glomerular
injury have described morphologic changes that may serve as a
basis for the reduction in LA: (1) separation and detachment of
the endothelial cell from the underlying GBM and (2) accumula-
tion and attachment of polymorphonuclear leukocytes to the
GBM [10, 11]. Because histamine is known to be released from
mast cells in the rat via activating complement components
[14], and because histamine is a cationic molecule, it remained a
significant possibility that high concentrations of histamine
released locally during immune-induced glomerular inflam ma-
tion might contribute to the observed separation of endothelial
cells from the GBM by interfering with interaction between the
predominantly electronegative cell and surface sites [11]. An-
other possibility is that histamine release might directly or
indirectly effect mesangial cell contraction and alter effective
glomerular ultrafiltering surface area, thereby influencing ]LA
[13, 23]. Therefore, there were a significant number of reason-
able potential mechanisms that would support a potential role
for histamine in contributing to some of the known mechanisms
leading to reductions in LA (Kf) after acute AGBM administra-
tion.
The previous literature would have suggested that H1 recep-
tor blockade was clearly the most likely to have provided a
beneficial effect and not the use of H2 receptor blockers [13].
The data clearly demonstrate no role for the H1 receptor at this
stage of AGBM-induced immune injury and no detectable role
for histamine in LA reduction. But the results in the H2
receptor antagonist (cimetidine)-treated group require some
further examination and discussion. Cimetidine infusion clearly
exerted a significant, nonimmune-related effect on the control,
plasma-expanded condition when compared with similarly plas-
ma-expanded control and receptor-blocker-treated groups.
The SNGFR, RPF, and zP were significantly lower in group 3
than they were in the control state, although the LA was
unaffected by cimetidine. This effect was the result of H2
receptor antagonist effects on AR and a lower mean arterial
pressure, suggesting a significant, nonrenal effect of cimetidine.
In addition, when AGBM was given, mean arterial pressure
decreased in the cimetidine group only. These nonrenal vascu-
lar events make the findings of AGBM effects on AR and ER
difficult to interpret. Although renal vascular resistance did not
change after AGBM administration in group 3, this may be a
nonspecific vascular effect of cimetidine [24—32] and should not
be interpreted as a unique, beneficial effect of H2 receptor
blockade. In the final analysis, SNGFR, RPF, and LA did
decrease in this group and no specific role for H2 receptors can
be defined in this model of immune injury.
Such investigations must also insure that utilization of such
histamine receptor antagonists exerted no nonspecific iriflu-
ences on the immune process, thereby influencing the results.
We have evaluated this issue specifically by examining the
quantitative binding of AGBM in untreated animals and those
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receiving H, (diphenhydramine) and H2 (cimetidine)-blocking
agents. There was no influence of these agents on AGBM
binding either via direct pharmacologic effects on antibody
fixation or via potential indirect effects on AGBM load via
influences on RPF. On a more qualitative level, immunofluores-
cence studies also revealed no differences in complement
deposition among groups, which suggests that these blockers do
not specifically interfere with complement activation or binding
after AGBM. Also, these agents did not affect serum CH50
levels. Therefore, the major immune mechanisms, with regard
to antibody binding, complement participation, and circulating
white blood cells, appear to be unaffected by the H, and H2
receptor antagonists used.
The present data do not speak to issues related to the later
phases of glomerular immune injury. But it seems unlikely that
later events would differ greatly regarding a role for histamine.
First, the effects of locally injected histamine are immediate and
should be evident early. Our previous studies have clearly
shown that major alterations in physiologic parameters
(SNGFR, RPF, and LA) and morphology are also observed
quite early, within 60 mm of AGBM administration, and that
polymorphonuclear leukocytes participate early in this inflam-
matory mechanism [10—12]. We can clearly state that histamine
does not mediate these effects on LA. To the extent that
reduction in LA could be mediated by mesangial contraction
and not solely explained by morphologic changes observed,
access of H1 and H2 receptor blockers to critical extravascular
sites in the mesangium might limit the use of such agents and
thereby underestimate the role of histamine in affecting LA
after AGBM administration. The evidence is currently lacking,
however, that mesangial activity affects either LA reduction
after immune injury or that histamine infusion reduces LA by
this mechanism.
A final point should be noted. The data obtained in group 3
suggest that changes in AR and ER can be separated from the
changes in LA in this early phase of glomerular immune injury.
In general, changes in resistances and LA have occurred
simultaneously following AGBM, and these data demonstrate
that vasoconstriction and alterations in glomerular permeability
and surface area are distinctly separate and likely produced by
different mechanisms.
Histamine, acting via the H1 receptor, does not appear to
participate in the alterations in glomerular ultrafiltration that
occur shortly after administration of AGBM. In addition,
neither H1 nor H2 receptor activation appears to participate in
the reduction in glomerular permeability, which is characteris-
tic of this model of acute immune injury. Blockade of H2
histamine receptors does appear to modify characteristic in-
creases in both afferent and efferent vascular resistance, but we
are reluctant to conclude that this is a specific effect of H2
receptor blockade relevant to glomerular immune injury. There-
fore, we conclude that histamine plays no major role in the
mechanism of the glomerular immune injury that follows acute
administration of large doses of AGBM in the rat.
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